Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease
28/10/2024 18:31
Oct 28 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN
PATENT
COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL
DISEASE
Source text: ID:nGNXbbw47D
Further company coverage: ABS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041